appoints Michael Uhlin as
Chief Scientific Officer
XNK Therapeutics Reports First Patient
Included in Phase II Study
in Multiple Myeloma
Individualized NK Cell Therapies
XNK Therapeutics AB is an immunotherapy company focusing its efforts on preventing and treating cancer by developing novel NK cell-based therapies. The company’s platform-technology and leading investigational autologous drug candidate, CellProtect, has ideal properties for targeting cancers, including settings where allogeneic cell products are not readily applicable. It is foreseen that the product will bring a critical component to tomorrow’s cancer treatment strategies.
July 1, 2021 Non RegulatoryXNK Therapeutics Reports First Patient Included in Phase II Study in Multiple Myeloma
June 29, 2021 Non RegulatoryReport from Annual General Meeting in XNK Therapeutics AB (publ)
CellProtect, autologous ex vivo expanded and activated NK cells with potent anti-cancer activity, is the company’s lead investigational drug candidate. CellProtect is intended to be utilized in specialized clinic as well as in open-care settings.